sanofi dropping larotaxel

sanofi-aventis Group (Euronext:SAN; NYSE:SNY) reported 4Q09 earnings on Wednesday and said it terminated development of larotaxel, a second-generation taxoid in Phase III testing for advanced pancreatic and bladder cancer. The pharma also stopped development of two compounds in Phase II testing: SAR407899, a Rho-kinase inhibitor for erectile dysfunction (ED); and ataciguat, a guanylate cyclase activator for neuropathic pain. Further details were not disclosed. ...